Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya3363410.26442/00403660.2019.08.000385Research ArticleTreatment of candidemia caused by Candida albicans and Candida non - albicans in patients with hematological malignanciesKlyasovaG Aklyasova.g@blood.ruMalchikovaA O-TandilovaK S-BlohinaE V-ParovichnikovaE N-KravchenkoS K-SavchenkoV G-National Research Center for HematologySechenov First Moscow State Medical University (Sechenov University)15082019918849216042020Copyright © 2019, Consilium Medicum2019Aim. To study the risk factors, symptoms and outcomes of candidemia caused by C. albicans and C. non - albicans in patients with hematological malignancies. Materials and methods. The study included patients with hematological malignancies and candidemia. The diagnosis of candidemia was established according to the single isolation of Candida spp. from blood culture and the presence of symptoms of infection. Results and discussion. Over 12 years (2006-2017), candidemia was diagnosed in 75 patients aged 17 to 77 years (median 48 years). The causative agents of candidemia were C. albicans in 34.7% of patients, C. non - albicans - in 65.3%. Candidemia caused by C. albicans prevailed in patients of the older age group (median 56.5 years, p=0.04) and in patients with lymphoma (61.5%, p=0.01) with colonization of the gut by the same species of Candida (88.5%, p=0.002). Isolation of C. non - albicans from blood culture was more common in patients with acute leukemia (51%, p=0.01) and in recipients of allogeneic hematopoietic stem cells (22.5%, p=0.01). The ability to form biofilms was observed more frequently among C. non - albicans (59.2%) than C. albicans (19.2%, p=0.001). The clinical symptoms of candidemia were non - specific (fever was in 97%). Septic shock developed in 25 (33%) patients with comparable frequency in both groups. Concomitant infections was also comparable (73% vs. 73.5%). Overall 30-day survival in patients with candidemia caused by C. albicans and C. non - albicans was 61.2% and 61.5%. Treatment with echinocandin was associated with increase of survival compared to other antifungal agents among patients with C. albicans candidaemia (88.9% versus 40%, p=0.02) and among C. non - albicans (77.3% versus 47.8%). Conclusion. C. non - albicans constituted a high proportion among causative agents of candidemia. High mortality rate was observed in both groups. Initial therapy with echinocandin was associated with increase of survival.Candida sppcandidemiaCandida spphematological malignanciesкандидемииопухоли системы крови[Клясова Г.А., Сперанская Л.Л., Миронова А.В., Масчан М.А. Байдильдина Д.Д., Верещагина С.А., Капорская Т.С., Юрицина Н.Ю., Поспелова Т.И., Крайнова Л.Е. Маркина О.А. Трушина Е.Е., Бриллиантова А.Н., Фролова И.Н. Возбудители сепсиса у иммунокомпрометированных больных: структура и проблемы антибиотикорезистентности (результаты многоцентрового исследования). Гематология и трансфузиология. 2007;(1):11-9.][Barchiesi F, Orsetti E, Gesuita R, Skrami E, Manso E. Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. Infection. 2016;44(2):205-13. doi: 10.1007/s15010-015-0845-z][Montagna M.T, Lovero G, Borghi E, Amato G, Andreoni S, Campion L, Lo Cascio G, Lombardi G, Luzzaro F, Manso E, Mussap M, Pecile P, Perin S, Tangorra E, Tronci M, Iatta R, Morace G. Candidemia in intensive care unit: a nation wide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci. 2014;18(5):661-74.][De Pauw B, Walsh T.J, Donnelly P, Stevens D.A, Edwards J.E, Calandra T, Pappas P, Maertens J, Lortholary O, Kauffman C.A, Denning D.W, Patterson T.F, Maschmeyer G, Bille J, Dismukes W.E, Herbrecht R, Hope W.W, Kibbler C.C, Kullberg B.J, Marr K.A, Muñoz P, Odds F.C, Perfect J.R, Restrepo A, Ruhnke M, Segal B.H, Sobel J.D, Sorrell T.C, Viscoli C, Wingard J.R, Zaoutis T, Bennett J.E. Revised definitions of invasive fungal disease from European organization for research and treatment of invasive fungal disease from European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group EORTC/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813-21. doi: 10.1086/588660][Tumbarello M, Fiori B, Trecarichi E.M, et al. Risk factors and outcomes of candidemia caused by biofilm - forming isolates in a tertiary care hospital. PLoS One. 2012;7:e33705. doi: 10.1371/journal.pone.0033705][Pierce C.G, Uppuluri P, Tristan A.R, et al. A simple and reproducible 96 well plate - based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc. 2008;3(9):1494-500. doi: 10.1038/nport.2008.141][Melo A.S, Bizerra F.C, Freymuller E, Arthington-Skaggs B.A, Colombo A.L. Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol. 2011;49:253-62. doi: 10.3109/13693786.2010.530032][Segal B.H, Herbrecht R, Stevens D.A, Ostrosky-Zeichner L, Sobe J, Viscoli C, Walsh T.J, Maertens J, Patterson T.F, Perfect J.R, Dupont B, Wingard J.R, Calandra T, Kauffman C, Graybill J.R, Baden L.R, Pappas P.G, Bennett J.E, Kontoyiannis D.P, Cordonnier C, Viviani M.A, Bille J, Almyroudis N.G, Wheat L.J, Graninger W, Bow E, Holland S, Kullberg B, Dismukes W, De Pauw B. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis. 2008;47(5):674-83. doi: 10.1086/590566][Sipsas N.V, Lewis R.E, Tarrand J, Hachem R, Rolston K.V, Raad II, Kontoyiannis D.P. Candidemia in patients with hematologic malignanses in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Canсer. 2009;115(20):4745-52. doi: 10.1002/cncr.24507][Gong X, Luan T, Wu X, Li G, Qiu H, Kang Y, Qin B, Fang Q, Cui W, Qin Y, Li J, Zang B. Invasive candidiasis in intensive care units in China: Risk factors and prognoses of Candida albicans and non - albicans Candida шnfections. Am J Infect Control. 2016 Jan 15;1-5.][Kliasova G, Okhmat V, Popova M, et al. Russian Prospective Multicenter Observational Study of Invasive Fungal Infections (IFI) in patients with Acute Leukemia (AL) and Hematopoietic Stem Cell Transplantant (HSCT) Recipients - RIFI. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC). Washington, 2014, М-1103.][Lamoth F, Lockhart S.R, Berkow E.L, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(1):4-13. doi: 10.1093/jac/dkx444][Arendrup M.С, Dzajic E, Jеnsen R.H, Johansen N.K, Kjaeldgaard P, Knudsen J.D, Kristensen L, Leitz C, Lemming L.E, Nielsen L, Olesen B, Rosenvinge F.C, Røder B.L, Schønheyder H.C. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013;19(8):343-53. doi: 10.1111/1469-0691.12212][Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112(11):2493-9. doi: 10.1002/cncr.23466][Montagna М.Т, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, Iatta R, Giglio M, Dalfino L, Bruno F, Puntillo F. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection. 2013;41(3):645-53. doi: 10.1007/s15010-013-0432-0][Pappas P.G, Lionakis M.S, Arendrup M.C, Ostrosky Zeichner L, Kullberg B.J. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi: 10.1038/nrdp.2018.26][Rausch C.R, Di Pippo A.J, Bose P, Kontoyiannis D.P. Breakthrough fungal infections in leukemia patients receiving isavuconazole. Clin Infect Dis. 2018;67(10):1610-3. doi: 10.1093/cid/ciy406][Drgona L, Kosmanova I, Rolencova M, Sedlacek P, Chrenkova V, Horakova J, Dzurenkova A, Zak P, Zavrelova A, Guman T, Tothova E, Mudry P, Foralova R, Novak J, Vokurka S, Kouba M, Ziakova B, Ligova A, Muzik J, Kandrnal V, Mayer J, Racil Z. Invasive candidemia/candidiasis on hematological wards in 2000-2012- a results from FIND-Candida project. Trends in Medical Mycology (TIMM). 2013;56(3):55-167.][Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, Caramatti C, Castagnola C, Cattaneo C, Fanci R, Chierichini A, Melillo R, Mitra M.E, Picardi M, Potenza L, Salutari P, Vianelli N, Facchini L, Cesarini M, De Paolis M.R, Di Blasi R, Farina F, Venditti A, Ferrari A, Garzia M, Gasbarrino C, Invernizzi R, Lessi F, Manna A, Martino B, Nadali G, Offidani M, Paris L, Pavone V, Rossi G, Spadea A, Specchia G, Trecarichi E.M, Vacca A, Cesaro S, Perriello V, Aversa F, Tumbarello M, Pagano L. Pre - chemotherapy risk factors for invasiv fungal diseases: prospectiv analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica. 2015;100(2):284-92. doi: 10.3324/haematol.2014.113399][Gamaletsou M.N, Walsh T.J, Zaotis T, Pagoni M, Kotsopoulou M, Voulgarelis M, Panayiotidis P, Vassilakopoulos T, Angelopoulou M.K, Marangos M, Spyridonidis A, Kofteridis D, Pouli A, Sotiropoulos D, Matsouka P, Argyropoulou A, Perloretzou S, Leckerman K, Manaka A, Oikonomopoulos P, Daikos G, Petrikkos G, Sipsas N.V. A prospective, cohort, multicentre study of candidemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20(1):50-7. doi: 10.1111/1469-0691.12312][Dalle F, Lafon I, L'ollivier C, Ferrant E, Sicard P, Labruère C, Jebrane A, Laubriet A, Vagner O, Caillot D, Bonnin A. A prospective analysis of the genotypic diversity and dynamicsof the Candida albicans colonizing flora in neutropenic patients with denovo acute leukemia. Haematologica. 2008;93(4):581-7. doi: 10.3324/haematol.11882][Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis. 2001;33(12):1959-67. doi: 10.1086/323759][Pagano L, Mele L, Fianchi L, Melillo L, Martino B, D'Antonio D, Tosti M.E, Posteraro B, Sanguinetti M, Trapè G, Equitani F, Carotenuto M, Leone G. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica. 2002;87(5):535-41.][Anttila V.J, Lamminen A.E, Bondestam S, Korhola O, Farkkila M, Sivonen A, Ruutu T, Ruutu P. Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. Eur J Haematol. 1996;56(1-2):82-7.][Andes D.R, Safdar N, Baddley J.W, Playford G, Reboli A.C, Rex J.H, Sobel J.D, Pappas P.G, Kullberg B.J. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient - level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110-22. doi: 10.1093/cid/cis021][Ullmann A, Akova M, Herbrecht R, Viscoli C, Arendrup M.C, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely O.A, Donnelly J.P, Garbino J, Groll A.H, Hope W.W, Jensen H.E, Kullberg B.J, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson M.D, Roilides E, Verweij P.E, Cuenca-Estrella M. ESCMID guidelines for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation. Clin Microbiol Infect. 2012;18(7):53-67. doi: 10.1111/1469-0691.12041][Pappas P.G, Kauffman C.A, Andes D.R, Clancy C.J, Marr K.A, Ostrosky-Zeichner L, Reboli A.C, Schuster M.G, Vazquez J.A, Walsh T.J, Zaoutis T.E, Sobel J.D. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):1-50. doi: 10.1093/cid/civ933][Клясова Г.А., Блохина Е.В., Грачева А.Н., Кравченко С.К., Паровичникова Е.Н., Охмат В.А., Коробова А.Г., Галстян Г.М., Куликов С.М. Факторы, влияющие на излечение у больных гемобластозами и кандидемией. Терапевтический архив. 2015;87(7):77-87. doi: 10.17116/terarkh201587777-87]